US-based pharmaceutical major Moderna's experimental vaccine, mRNA-1273, created to protect against Covid-19 virus, was generally well tolerated and prompted neutralising antibody activity in healthy adults, say researchers.
The upcoming Phase 3 trial, which will commence from July 27, will recruit 30,000 participants in the U.S., with half to receive the vaccine at 100 microgram dose levels, and the other half to receive a placebo.
"Vaccine shown to provide an immune boost in 45 volunteers". Two doses of vaccine prompted high levels of neutralising antibody activity that was above the average values seen in convalescent sera obtained from persons with confirmed Covid-19 disease.
There's no guarantee but the government hopes to have results around the end of the year - record-setting speed for developing a vaccine. The vaccine demands two doses, one month apart. Some participants experienced mild side effects such as fatigue, chills, headache and weakness. Subjects were divided into three groups of 15, each of which was given different doses of the vaccine.
Some of those reactions are similar to coronavirus symptoms but they're temporary, lasting about a day and occur right after vaccination, researchers noted.
According to the Sechenov University Center For Clinical Research on Medications chief researcher Elena Smolyarchuk, human trials were now "completed" after 20 patients volunteered and were quarantined for 28 days.
PS5 Production Doubles As 'Sony Orders 10 Million Units' In 2020
However, Nikkei now reports that number has gone up to 9 million , and Bloomberg's estimate is even higher at 10 million units. It's important to note that all 10 million units might not be available on store shelves before the end of the year.
Stimulating the production of antibodies is considered a key milestone in early testing, but doesn't prove a vaccine will be effective, Bloomberg said.
In April, the trial was expanded to enroll adults older than age 55 years; it now has 120 participants.
"Most people make them (antibodies), but often they can wane rather rapidly, suggesting there could be little immunity", said Daniel Altmann, a professor of immunology at Imperial College London.
Although, it is not clear how long the vaccine can prevent the virus, the study said the 45 participants will be monitored for a long time. Researchers from China and Britain's Oxford University also are entering the final testing stages.
As for ZyCoV-D, developed in the Vaccine Technology Centre in Ahmedabad, pre-clinical studies were done on multiple animal species like mice, rats, guinea pigs, and rabbits. The recruitment for volunteers is expected to start in September.
"If your vaccine can induce a response comparable with natural infection, that's a victor", Fauci said in a telephone interview.